This is complex but I agree with Cass that a trial should be set up.
A proper trial should have a clear requirement that all participants, and for those under 16 (18) their parents, must give informed consent. As we know from the WPATH files there is significant doubt that anyone, child or parent, can give informed consent. That is a huge stumbling block.
Puberty blockers have historically been used more responsibly in the case of precocious puberty. The NHS defines this as where a girl under 8 or a boy under 9 shows signs of early puberty. The aim is not to stop puberty but to pause it for a short period.
I would want the first part of a trial to focus on children who have precocious puberty and received puberty blockers for a short time before going through puberty. This would need to be a long term trial with high quality data collection and follow up to assess the impact on adult health e.g. fertility, bone density etc. If there is evidence of an impact then a trial to prevent puberty would be unethical.
The trial could also follow up all the children who previously received puberty blockers long term and so did not go through puberty. Again this would need to be a long term study requiring high quality data collection and analysis. Sadly de-transitioners may be the most help.
There is also the question of delayed puberty as this can be the point children with undiagnosed DSD are identified. A trial may need to consider the right options for children with DSD. Again it would initially be about data collection and analysis rather than trialling puberty blockers. This is a particularly sensitive area as historically people with DSD have been subjected to horrifying treatment by medical professionals in the name of science.
A trial in my view does not start with prescribing puberty blockers rather taking a step back and looking for the evidence that already exists and following it up. First do no harm.